`with Small Molecule Drugs
`
`Privileged and Confidential
`Attorney Work Product
`2921.065IPR0
`
`-
`-
`-
`
`-
`
`Braslawsky
`Braslawsky
`US5068227
`
`EP0495265
`
`-
`-
`-
`
`Hinman
`Trail
`SGN15
`
`Starling
`
`Elias
`
`Johnson
`
`Hamann
`Hamann
`HuN901-DM1
`My9-6-DM1
`*
`Bivatuzumab mertansine
`
`*
`
`-
`-
`-
`-
`-
`
`*
`
`Trastuzumab-auristatin
`BB-10901-DM1 (in humans)
`Jeffrey
`Jeffrey
`HuMy9-DM1
`SGN-75
`
`*
`
`-
`-
`-
`-
`-
`-
`
`Phillips
`Phillips
`
`-
`-
`
`Chari *
`
`CMB-401
`Chari *
`Chari *
`Mylotarg approval
`
`-
`-
`-
`-
`
`Chari Lui Review published
`
`Tolcher
`*
`Doronina
`
`-
`-
`
`Beck
`Beck
`
`-
`-
`
`- Myeloma
`-
`Tang *
`
`-
`-
`
`Kellog
`Kellog
`
`1987
`
`1989
`
`1990
`
`1991
`
`1993
`
`1995
`Chari
`
`1992
`Chari *
`Chari *
`
`-
`-
`
`1996
`
`1997
`
`1998
`Chari review
`
`2000
`
`2001
`Blättler
`
`2002
`
`2003
`
`yellow = cleavable linker
`= maytansinoid drug
`= non-cleavable linker
`
`pink
`
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`
`*
`
`2005
`
`-
`-
`
`2004
`Henry
`Lillo
`Lillo
`HuC242-DM4
`*
`HuC242-DM4
`*
`AntiCD22-Calicheamicin
`rituximab
`Hu3S193-NAc-Calicheamicin
`cAC10-MMAE
`CMC544
`
`2006
`TSE
`Tijink
`
`2007
`
`2008
`
`2009
`
`2010
`Polson *
`
`-
`
`2011
`
`2012
`
`1919024_2
`
`IMMUNOGEN 2095, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676